117 filings
Page 5 of 6
8-K
gutax2amz4i6 anh9
7 Nov 18
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results
5:22pm
8-K
22mved avpni6tirfys
10 Oct 18
Regulation FD Disclosure
5:25pm
8-K
crzfl c1h3
24 Sep 18
Entry into a Material Definitive Agreement
5:27pm
8-K
vf2mpp4pxb
21 Sep 18
Crispr Therapeutics Announces Proposed Public Offering of Common Shares
4:16pm
8-K
17yipu59ou1ykahms6g
17 Sep 18
CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes
12:00am
8-K
ml7wn
11 Sep 18
Other Events
12:00am
8-K
um3jac
31 Aug 18
Entry into a Material Definitive Agreement
12:00am
8-K
9g36mu 1l6h
7 Aug 18
Reports Second Quarter 2018 Financial Results
5:10pm
8-K
2e58b20mpunhvd
1 Jun 18
Departure of Directors or Certain Officers
5:05pm
8-K
cqa5w
30 May 18
CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug
4:37pm
8-K
86cpy3cv2p4q08hdx
8 May 18
Reports First Quarter 2018 Financial Results
7:43am
8-K
14ga0rjrwsvemt
8 Mar 18
Reports Fourth Quarter and Full Year 2017 Financial Results
12:00am
8-K
jz6q63qk0n6t6j
5 Jan 18
CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
12:00am
8-K
7ckogvo9zf4782ofku
21 Dec 17
CRISPR Therapeutics Announces Appointment of Dr. Rodger Novak as Chairman of the Board
12:00am
8-K
psensiwd
18 Dec 17
Vertex and CRISPR Therapeutics toCo-Develop andCo-Commercialize
12:00am
8-K
c8ejhfta9cv
7 Dec 17
Other Events
12:00am
8-K
4m4s35h ifkpkxttx
13 Nov 17
CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer
12:00am
8-K
695gwkc5oihy5ytk t8o
8 Nov 17
CRISPR Therapeutics Announces Third Quarter 2017 Financial Results
12:00am
8-K
doh01l0r0zttmgmj77
7 Nov 17
Other Events
12:00am
8-K
bon6oz
2 Oct 17
CRISPR Therapeutics Announces Promotion of
12:00am